Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal for Equity in Health
Published in: International Journal for Equity in Health 1/2005

Open Access 01-12-2005 | Research

Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need

Authors: Paul R Ward, Peter R Noyce, Antony S St Leger

Published in: International Journal for Equity in Health | Issue 1/2005

Login to get access

Abstract

Background

There is a small, but growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The aim of this paper is to further explore the equity of prescribing for five major CHD drug groups and to explain the amount of variation in GP practice prescribing rates that can be explained by a range of healthcare needs indicators (HCNIs).

Methods

The study involved a cross-sectional secondary analysis in four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices. Prescribing rates (average daily quantities per registered patient aged over 35 years) and HCNIs were developed for all GP practices. Analysis was undertaken using multiple linear regression.

Results

Between 22–25% of the variation in prescribing rates for statins, beta-blockers and bendrofluazide was explained in the multiple regression models. Slightly more variation was explained for ACE inhibitors (31.6%) and considerably more for aspirin (51.2%). Prescribing rates were positively associated with CHD hospital diagnoses and procedures for all drug groups other than ACE inhibitors. The proportion of patients aged 55–74 years was positively related to all prescribing rates other than aspirin, where they were positively related to the proportion of patients aged >75 years. However, prescribing rates for statins and ACE inhibitors were negatively associated with the proportion of patients aged >75 years in addition to the proportion of patients from minority ethnic groups. Prescribing rates for aspirin, bendrofluazide and all CHD drugs combined were negatively associated with deprivation.

Conclusion

Although around 25–50% of the variation in prescribing rates was explained by HCNIs, this varied markedly between PCTs and drug groups. Prescribing rates were generally characterised by both positive and negative associations with HCNIs, suggesting possible inequities in prescribing rates on the basis of ethnicity, deprivation and the proportion of patients aged over 75 years (for statins and ACE inhibitors, but not for aspirin).
Literature
1.
Goddard M, Smith P: Equity of access to health care services: theory and evidence from the UK. Soc Sci Med. 2001, 53: 1149-1162. 10.1016/S0277-9536(00)00415-9.CrossRefPubMed
2.
Whitehead M: The concepts and principles of equity and health. Int J Health Serv. 1992, 22: 429-445.CrossRefPubMed
3.
Williams A, Cookson R: Equity in health. Handbook of Health Economics. Edited by: Culyer AJ and Newhouse J. 2000, Amsterdam, Elsevier
4.
Ward PR, Noyce PR, St Leger AS: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health. 2004, 58: 89-96. 10.1136/jech.58.2.89.CrossRefPubMedPubMedCentral
5.
Tudor Hart J: The inverse care law. Lancet. 1971, i: 405-412. 10.1016/S0140-6736(71)92410-X.CrossRef
6.
Health D: National Service Frameworks for Coronary Heart Disease. 2000, London, Stationary Office
7.
Rice N, Dixon P, Lloyd DC, Roberts D: Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. BMJ. 2000, 320: 284-288. 10.1136/bmj.320.7230.284.CrossRefPubMedPubMedCentral
8.
Lloyd DC, Scrivener G: Prescribing at the Primary Care Group level: census data and prescribing indicators. J Clin Pharm Therapeutics. 2001, 26: 93-101. 10.1046/j.1365-2710.2001.00320.x.CrossRef
9.
Majeed A, Cook DG, Evans N: Variations in general practice prescribing costs - implications for setting and monitoring prescribing budgets. Health Trends. 1996, 28: 52-55.
10.
11.
Pringle M, Morton-Jones T: Using unemployment rates to predict prescribing trends in England. Br J Gen Pract. 1994, 44: 53-56.PubMedPubMedCentral
12.
13.
Majeed A, Moser K, Maxwell R: Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med. 2000, 22: 275-279. 10.1093/pubmed/22.3.275.CrossRefPubMed
14.
Packham C, Pearson J, Robinson J, Gray D: Use of statins in general practices, 1996-8: cross sectional study. BMJ. 2000, 320: 1583-1584. 10.1136/bmj.320.7249.1583.CrossRefPubMedPubMedCentral
15.
Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D: Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med. 1999, 21: 60-64. 10.1093/pubmed/21.1.60.CrossRefPubMed
16.
Reid FDA, Cook DG, Whincup PH: Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. Heart. 2002, 88: 15-19. 10.1136/heart.88.1.15.CrossRefPubMedPubMedCentral
17.
Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP: Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart. 2002, 88: 159-162. 10.1136/heart.88.2.159.CrossRefPubMedPubMedCentral
18.
Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A: Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ. 2001, 322: 832-10.1136/bmj.322.7290.832.CrossRefPubMedPubMedCentral
19.
Primatesta P, Poulter NR: Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000, 321: 1322-1325. 10.1136/bmj.321.7272.1322.CrossRefPubMedPubMedCentral
20.
Patel MG, Wright DJ, Gill PS, Jerwood D, Silcock J, Chrystyn H: Prescribing of lipid lowering drugs to South Asian patients: ecological study. BMJ. 2002, 325: 25-26. 10.1136/bmj.325.7354.25.CrossRefPubMedPubMedCentral
21.
Gibson A, Asthana S, Brigham P, Moon G, Dicker J: Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health & Place. 2002, 8: 47-60. 10.1016/S1353-8292(01)00035-1.CrossRef
22.
Wang TJ, Stafford RS: National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med. 1998, 158: 1901-1906. 10.1001/archinte.158.17.1901.CrossRefPubMed
23.
Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998, 339: 489-497. 10.1056/NEJM199808203390801.CrossRefPubMed
24.
Bradshaw N, Fone DL, Walker R: Explaining variation in statin prescribing: a practice based analysis. Pharm J. 1999, 263: R19-
25.
Health D: The New NHS: Modern, Dependable. 1998, London, HMSO
26.
Health D: Primary Care Trusts, Establisging Better Services. 1999, London, NHS Executive
27.
Health D: Shifting the Balance of Power: Next Steps. 2002, London, The Stationary Office
28.
Peckham S, Taylor P: Public health and primary care. Public Health for the 21st Century. New Perspectives on policy, participation and practice. Edited by: Orme J, Powell J, Taylor P, Harrison T and Grey M. 2003, Maidenhead, Open Universtity Press
29.
Ward PR, Noyce PR, St Leger AS: Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins. J Clin Pharm Ther. 2003, 28: 23-29. 10.1046/j.1365-2710.2003.00451.x.CrossRefPubMed
30.
Ward PR, Noyce PR, St Leger AS: Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England. Therapeutics and Clinical Risk Management. 2005, 1: 61-68.CrossRefPubMedPubMedCentral
31.
Chapman SR: Prescribing information systems; making sense of primary care data. J Clin Pharm Therapeutics. 2001, 26: 235-239. 10.1046/j.1365-2710.2001.00352.x.CrossRef
32.
33.
Hopper S, Pierce P: Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract. 1998, 15: S10-S13.PubMed
34.
Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM: Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ. 1998, 316: 1430-1434.CrossRefPubMedPubMedCentral
35.
Bedson J, Whitehurst T, Lewis M, Croft P: Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract. 2001, 51: 1001-1003.PubMedPubMedCentral
36.
Steg PG, Iung B, Feldman LJ, Cokkinos D, Deckers J, Fox KAA, Keil U, Maggioni AP: Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart. 2002, 88: 20-24. 10.1136/heart.88.1.20.CrossRefPubMedPubMedCentral
37.
Group. EUROASPIREII: Liefstyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001, 22: 554-572. 10.1053/euhj.2001.2610.CrossRef
38.
Frischer M, Chapman SR: Issues and Directions in Prescribing Analysis. Medicines Management. Edited by: Panton R and Chapman SR. 1998, London, Pharmaceutical Press
39.
40.
Unit PS: Defined Daily Doses, Prescribed Daily Doses and Average Daily Quantities. 1997, Leeds, Prescribing Support Unit
41.
Organisation. WH: Guideline for Defined Daily Doses. 1991, Oslo, WHO Collaborating Centre for Drug Statistics
42.
Walley T, Roberts DJ: Average daily quantities: a tool for measuring prescribing volume in England. Pharmacoepidemiol Drug Safety. 2000, 9: 55-58.CrossRef
43.
Unit PS: Average Daily Quantities and STAR(97)-PUs. 2000, Leeds, PSU
44.
Statistics ON: Key Statistics from General Practice. 1998, London, ONS
45.
Tunstall-Pedoe H: Cardiovascular diseases. Oxford Textbook of Public Health. Volume 3. The Practice of Public Health. Edited by: Detels R, Holland W, McEwan J and Omenn GS. 1997, Oxford, Oxford Medical Publications, 3rd Edition
46.
Langham S, Normand C, Piercy J, Rose G: Cornary Heart Disease. Health Care Needs Assessment. The Epidemiologically Based needs Assessment Reviews. Edited by: Stevens A and Raftery J. 1994, Oxford, John Radcliffe Medical Press, 341-378. Volume 1
47.
Unit JHS: Health Survey for England 1998. 1999, London, The Stationary Office
48.
Chaturvedi N, Fuller J: Ethnic differences in mortlaity from cardiovascular disease in the UK: do they persist in people with diabetes?. J Epidemiol Community Health. 1996, 50: 137-139.CrossRefPubMedPubMedCentral
49.
Foundation BH: Coronary Heart Disease Statistics. British Heart Foundation Database 2002. 2002
50.
Bhopal R: What is the risk of coronary heart disease in South Asians? A review of the UK research. J Public Health Med. 2000, 22: 375-385. 10.1093/pubmed/22.3.375.CrossRefPubMed
51.
Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, Tavridou A: Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ. 1999, 319: 215-220.CrossRefPubMedPubMedCentral
52.
Nazroo JY: The Health of Britain's Ethnic Minorities. 1997, London, Policy Studies Institute
53.
Cooper H: Investigating socio-economic explanations for gender and ethnic inequalities in health. Soc Sci Med. 2002, 54: 693-706. 10.1016/S0277-9536(01)00118-6.CrossRefPubMed
54.
Mann JI, Marmot MG: Epidemiology of ischaemic heart disease. Oxford Textbook of Medicine. Volume II. Edited by: Weatherall DJ, Ledingham JGG and Warrell DA. 1987, Oxford, Oxford Medical Publications, Second Edition
55.
Townsend P, Phillimore P, Beattie A: Health and Deprivation: Inequality and the North. 1988, London, Croon Helm
56.
Whitehead M: The health divide: inequalities in health in the 1980s. 1987, London, Health Education Authority
57.
Salomaa V, Miettinen H, Niemela M, Ketonen M, Mahonen M, Immonen-Raiha P, Lehto S, Vuorenmaa T, Koskinen S, Palomaki P, Mustaniemi H, Kaarsalo E, Arstila M, Torppa J, Kuulasmaa K, Puska P, Pyorala K, Tuomilehto J: Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. J Epidemiol Community Health. 2001, 55: 475-482. 10.1136/jech.55.7.475.CrossRefPubMedPubMedCentral
58.
Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevant J, Weinstein MC: The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997, 277: 535-542. 10.1001/jama.277.7.535.CrossRefPubMed
59.
Jousilahti P, Vartianen E, Tuomilehto J, Pekkanen J, Puska P: Effect of risk factors and changes in risk factors on coronary mortality in three cohorts of middle-aged people in eastern Finland. Am J Epidemiol. 1995, 141: 50-60.PubMed
60.
Hope B: UK lags behind in fight against heart disease. BMJ. 1999, 318: 1229-PubMed
61.
Davey-Smith G, Hart C, Blane D: Lifetime socioeconomic position and mortality: prospective observational study. BMJ. 1997, 314: 547-552.CrossRef
62.
Davey-Smith G: Down at heart - the meaning and implications of social inequalities in cardiovascular disease. J Roy Coll Physicians. 1997, 31: 414-424.
63.
Suadicani P, Hein HO, Gyntelberg F: Socioeconomic status and ischaemic heart disease mortality in middle- aged men: importance of the duration of follow-up. The Copenhagen Male Study. Int J Epidemiol. 2001, 30: 248-255. 10.1093/ije/30.2.248.CrossRefPubMed
64.
65.
66.
Haynes RM, Lovett AA, Gale SH, Brainard JS, Bentham G: Evaluation of methods for calculating census health indicators for GP practices. Public Health. 1995, 109: 369-374.CrossRefPubMed
67.
Crayford T, Shanks J, Bajekal M, Langford S: Analysis from Inner London of deprivation payments based on enumeration districts rather than wards. BMJ. 1995, 311: 787-788.CrossRefPubMedPubMedCentral
68.
Kerrison S, Macfarlane A: Official Health Statistics. An Unofficial Guide. 2000, London, Arnold
69.
Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A: Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002, 88: 25-29. 10.1136/heart.88.1.25.CrossRefPubMedPubMedCentral
70.
Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001, 103: 38-44.CrossRefPubMed
71.
MacLeod MC, Finlayson AR, Pell JP, Findlay IN: Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland. Heart. 1999, 81: 252-256.CrossRefPubMedPubMedCentral
72.
Majeed FA, Cook D: Age and sex differences in the management of ischaemic heart disease. Public Health. 1996, 110: 7-12. 10.1016/S0033-3506(96)80027-8.CrossRefPubMed
73.
NHS Centre for Reviews and Dissemination: Cholesterol and coronary heart disease: screening and treatment. Effective Health Care Bulletin. 1998, 1: 4
74.
75.
Tod AM, Read C, Lacey A, Abbott J: Barriers to uptake of services for coronary heart disease: qualitative study. BMJ. 2001, 323: 214-10.1136/bmj.323.7306.214.CrossRefPubMedPubMedCentral
Metadata
Title
Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need
Authors
Paul R Ward
Peter R Noyce
Antony S St Leger
Publication date
01-12-2005
Publisher
BioMed Central
Published in
International Journal for Equity in Health / Issue 1/2005
Electronic ISSN: 1475-9276
DOI
https://doi.org/10.1186/1475-9276-4-3

Other articles of this Issue 1/2005

International Journal for Equity in Health 1/2005 Go to the issue

Commentary

Nepal's War on Human Rights: A summit higher than Everest

Research

Perceptions of substance use, treatment options and training needs among Iranian primary care physicians

Research

What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney

Research

The 1999 international emergency humanitarian evacuation of the Kosovars to Canada: A qualitative study of service providers' perspectives at the international, national and local levels

Commentary

The appearance of discretionary income: Influence on the prevalence of under- and over-nutrition

Research

User fees in private non-for-profit hospitals in Uganda: a survey and intervention for equity